<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940523-0-00033</title>
	</head>
	<body>
		<main>
			<p><!-- PJG STAG 4700 -->  <!-- PJG ITAG l=24 g=1 f=1 --> B. The  <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=1 f=3 --> kan <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=5 f=1 --> r <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=1 f=1 -->  Gene <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 1. Potential transfer of the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=1 f=3 --> kan <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=5 f=1 --> r <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=1 f=1 -->  gene to intestinal microorganisms and cells lining the intestinal lumen <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> a. Relevant source of  <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=1 f=3 --> kan <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=5 f=1 --> r <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=1 f=1 -->  gene available for possible transformation <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> b. Effect of digestion on the availability of the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=1 f=3 --> kan <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=5 f=1 --> r <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=1 f=1 -->  gene for transformation <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> c. Calculation of worst-case transformation frequencies <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 2. Potential transfer of the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=1 f=3 --> kan <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=5 f=1 --> r <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=1 f=1 -->  gene to soil microorganisms <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 3. Food Advisory Committee discussions regarding potential horizontal transfer of the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=1 f=3 --> kan <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=5 f=1 --> r <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=1 f=1 -->  gene <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 4. Agency conclusions <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 --> IV. Response to Comments <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=1 f=1 --> A. Regulatory Issues <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> B. Food Safety <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 1. Glycosylation <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 2. In vitro digestibility studies <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 3. Copy number of the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=1 f=3 --> kan <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=5 f=1 --> r <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=1 f=1 -->  gene and expression level of APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 4. The potential for side effects from consumption of genetically engineered foods <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 5. Relevance of clinical studies <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> C. Possible Effect on Clinical Efficacy of Orally Administered Kanamycin or Neomycin. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> D. Fate of the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=1 f=3 --> kan <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=5 f=1 --> r <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=1 f=1 -->  Gene in the Environment <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 1. Potential transfer of the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=1 f=3 --> kan <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=5 f=1 --> r <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=1 f=1 -->  gene from crops to microorganisms <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 2. Potential transfer of the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=1 f=3 --> kan <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=5 f=1 --> r <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=1 f=1 -->  gene to other crops and to wild relatives <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> E. Possible Effects of Consumption of Animal Feeds Containing APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II on Animals and Their Gut Microflora <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> F. Labeling of Foods Containing the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=1 f=3 --> kan <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=5 f=1 --> r <!-- PJG /ITAG -->  <!-- PJG ITAG l=24 g=1 f=1 -->  Gene and APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=26 g=1 f=1 --> V. Conclusions <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> VI. Inspection of Documents <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> VII. Environmental Impact <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> VIII. Objections <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> IX. References <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=84 g=1 f=1 --> I. Introduction <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=83 g=1 f=1 --> A. Regulatory History <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 --> In accordance with 21 CFR 10.85, Calgene, Inc., submitted to FDA on November 26, 1990, a request for advisory opinion regarding whether the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> kan <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> r <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  gene, a selectable marker, may be used in the production of genetically engineered tomato, cotton, and oilseed rape plants intended for human food and animal feed uses ( <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> kan <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> r <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  Gene: Safety and use in the production of genetically engineered plants, Docket Number 90A&hyph;0416). In the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  of May 1, 1991 (56 FR 20004), FDA announced that the request had been received and solicited comments from interested persons. The data submitted to the agency with the request for advisory opinion and the comments received were made available to the public at the Dockets Management Branch. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> Subsequent to the submission of the request for advisory opinion, FDA published its ``Statement of Policy: Foods Derived From New Plant Varieties'' (the 1992 policy statement) in the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  of May 29, 1992 (57 FR 22984). This policy statement clarified FDA's interpretation of the Federal Food, Drug, and Cosmetic Act (the act) with respect to human foods and animal feeds derived from new plant varieties, including plants developed by new methods of genetic modification such as recombinant deoxyribonucleic acid (DNA) techniques. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> In the 1992 policy statement, FDA stated that the postmarket authority under section 402(a)(1) of the act (21 U.S.C. 342(a)(1)) would continue to be the primary legal tool for ensuring the safety of whole foods derived from genetically modified plants. FDA also noted that under the statutory definition of ``food additive'' in section 201(s) of the act (21 U.S.C. 321(s)), the transferred genetic material and the intended expression products could be subject to regulation as food additives, if such material or expression products were not generally recognized as safe (GRAS) (57 FR 22984 at 22990). FDA further stated that the agency would use its food additive authority to the extent necessary to ensure public health protection (such as when an intended expression product in a food differs significantly in structure, function, or composition from substances found currently in food) (57 FR 22984 at 22990). <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> The 1992 policy statement specifically discussed selectable markers that provide antibiotic resistance in product selection and development. With such markers, both the antibiotic resistance gene and the gene product, unless removed, are expected to be present in foods derived from such plants. FDA stated: <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Selectable marker genes that produce enzymes that inactivate clinically useful antibiotics theoretically may reduce the therapeutic efficacy of the antibiotic when taken orally if the enzyme in the food inactivates the antibiotic. FDA believes that it will be important to evaluate such concerns with respect to commercial use of antibiotic resistance marker genes in food, especially those that will be widely used. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 02 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=20 g=1 f=1 --> (See 57 FR 22984 at 22988.) <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> Subsequently, in January 1993, Calgene requested that FDA convert its request for advisory opinion to a food additive petition under section 409 of the act. FDA then announced in the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=4 --> Federal Register <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  of July 16, 1993 (58 FR 38429), that a food additive petition (FAP 3A4364) had been filed by Calgene, Inc., 1920 Fifth St., Davis, CA 95616, proposing that the food additive regulations be amended to provide for the safe use of APH(3 <!-- PJG 0020 minuteslatlong --> &rsquo;)II as a processing aid in the development of new varieties of tomato, oilseed rape, and cotton. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> After completing its review of the data submitted by Calgene, FDA convened a public meeting of its Food Advisory Committee on April 6 through 8, 1994, to undertake a scientific discussion of the agency's approach to evaluating the safety of whole foods produced by new biotechnologies; a genetically modified tomato developed by Calgene containing the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> kan <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> r <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  gene served as an example and focus of the discussion. The membership of the standing committee was supplemented with temporary members and consultants to the committee, representing scientific disciplines appropriate to the evaluation of foods derived from new plant varieties developed using recombinant DNA techniques. <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> At the meeting, Calgene presented a summary of the data they considered adequate to show safety of the tomato, and FDA presented its evaluation of the data. The committee was asked to comment on the approach used by FDA to evaluate whole foods and specifically, on the approach used for the Calgene tomato (Ref. 1). During committee discussion of the Calgene and FDA presentations, the committee members generally expressed the view that the approach used by FDA to evaluate the safety of the tomato, including the safety of the  <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=3 --> kan <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=5 f=1 --> r <!-- PJG /ITAG -->  <!-- PJG ITAG l=11 g=1 f=1 -->  gene, was appropriate and that all relevant scientific questions had been adequately addressed. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG /STAG --></p>
		</main>
</body></html>
            